LIFE09200604007 Tabish - Homi Bhabha National Institute

More documents

Recommendations

Info

Materials and Methods Table 2: List of primers used for PCR and QRT-PCR Gene-exon/region, SNP, RE GSTM1 (Deletion) GSTT1 (Deletion) GSTP1-exon5 Val 105 Ile, Alw261 MPO-upstream G -463 A, AciI SULT1A1-exon7 Arg 213 His, HaeII Fas-Enhancer A -670 G, MvaI CyclinD1-splice site , A 870 G, ScrfI XRCC1-exon9 Arg 280 His, RsaI XRCC1-exon6 Arg 194 Trp, PvuII hOGG1-exon7 Ser 326 Cys, Fnu4H1 XPD-exon23 Lys 751 Gln, Pst1 p21 Ser 31 Arg, BlpI XRCC3-exon7 Thr 241 Met, NcoI XRCC1-exon10 Arg 399 Trp, MspI Forward and reverse primer sequences (5’-3’) F-CTGCCCTACTTGATTGATGGG R-CTGGATTGTAGCAGATCATGC F-TTCCTTACTGGTCCTCACATCTC R-TCACCGGATCATGGCCAGCA F-ACCCCAGGGCTCTATGGGAA R-TGAGGGCACAAGAAGCCCCT F-CGGTATAGGCACACAATGGTAG R-GCAATGGTTCAAGCGATTCTTC F-GTTGGCTCTGCAGGGTTTCTAGGA R-CCCAAACCCCCTGCTGGCCAGCACCC F-CTACCTAAGAGCTATCTACCGTTC R-GGCTGTCCATGTTGTGGCTGC F-GTGAAGTTCATTTCCATTCCGC R-GGGACATCACCCTCACTTAC F-CCAGTGGTACTAACCTAATC R-TCAGCACCAGTACCACA F-GCCCCGTCCCAGGTA R-AGCCCCAAGACCCTTT F-ACTGTCACTAGTCTCACCAG R-TGAATTCGGAAGGTGCTTGGGG F-CTATCATCTCCTGGCCCCC R-GCCCGCTCTGGATTATACG F-GTCAGAACCGGCTGGGGATG R-CTCCTCCCAACTCATCCCGG F-GCCTGGTGGTCATCGACTC R-ACAGGGCTCTGGAAGGCACTGCTCAG CTCACGCACC F-CCCCAAGTACACCCAGGTC R-TGTCCCGCTCCTCTCTCAGTAG PCR product (bp) 217 bp 459 bp 176 bp 350 bp 331 bp 331 bp 167 bp 200 bp 485 bp 207 bp 436 bp 300 bp 136 bp 242 bp 75
Materials and Methods p53-exon4 Pro 72 Arg, BstUI NAT2-exon2 Ile 114 Thr NAT2-exon2 Arg 197 Gln NAT2-exon2 Gly 286 Gln BRCA2-5’UTR G -26 A BRCA2-exon10 Asn 372 His mEH-exon4 Tyr 51 His GPX-exon1 Pro 198 Leu β-actin IFN MAFB MAPK10 GNG12 ZNF429 ARHGAP29 TMEFF1 F-GACCTGGTCCTCTGACTGCT R-GCATTGAGTCTCATGGAAG F-CAAATACAGCACTGGCATGG R-GGCTGATCCTTCCCAGAAAT F-CCTGCCAAAGAAGAAACACC R-GGGTCTGCAAGGAACAAAAT F-TCCTTGGGGAGAAATCTCGT R-GGGTGATACATACACAAGGGTTT F-AAATTTTCCAGCGCTTCTGA R-AATGTTGGCCTCTCTTTGGA F-AGCAAACGCTGATGAATGTG R-GTGGAAGTGACAAAATCTCCAA F-CTCTCAACTTGGGGTCCTGA R-GGCGTTTTGCAAACATACCT F-ACTGGGATCAACAGGACCAG R-TTGACATCGAGCCTGACATC F-ACACTGTGCCCATCTACGAGGG R-AGGGGCCGGACTCGTCATACT F-GGCACAACAGGTAGTAGGCG R-GCCACAGGACGTTCTGACAC F- GACGCAGCTCATTCAGCAG R- CTCGCACTTGACCTTGTAGGC F-GCGAAACCCAGCGTTCTTCAGG R- GGCTTGGATTCTCTCCCTTGCTG F- AGCAAGCACCAACAATATAGCC R-AGTAGGACATGAGGTCCGCT F-TGCAAGATGAAGCGACATGAA R-GCTCTGGGTAAGTGTCAAACAT F-TAAAGCTCTACCTCCGAGACC R- GGAACCCTTCGTACTGGCTC F-TGTGAGGGAGTCTGACGTAAG R-AAGTGTCCCCATTTGATCCAC 380 bp 139 bp 143 bp 92 bp 158 bp 150 bp 231 bp 213 bp 621 bp 173 bp 88 bp 119 bp 113 bp 240 bp 63 bp 149 bp 76
Page 1:
Genotype-Molecular Phenotype Correl
Page 7 and 8:
CONTENTS Page No Synopsis 1 List of
Page 9 and 10:
Synopsis
Page 11 and 12:
Synopsis Genotype-Molecular Phenoty
Page 13 and 14:
Synopsis Materials and Methods: 1.
Page 15 and 16:
Synopsis loading control. PCR produ
Page 17 and 18:
Synopsis 7.1 Percent cell death aft
Page 19 and 20:
Synopsis slides were then dried and
Page 21 and 22:
Synopsis range 41.77% - 90.95% at 5
Page 23 and 24:
Synopsis 5. Genotyping of genes: Ge
Page 25 and 26:
Synopsis G2/M arrest and delaying e
Page 27 and 28:
Synopsis may have an important bear
Page 29 and 30:
Synopsis References: 1. Bobba, R.;
Page 31 and 32:
Abbreviations MOPS : 3-(N-morpholin
Page 33 and 34:
List of Figures Fig. 28: Percent re
Page 35 and 36:
Chapter 1 Introduction
Page 37 and 38: Introduction In previous studies fr
Page 39 and 40: Introduction important carcinogenes
Page 41 and 42: Review of Literature The yet undeci
Page 43 and 44: Review of Literature Fig. 2: Incide
Page 45 and 46: Review of Literature sustained angi
Page 47 and 48: Review of Literature 2.6 Genotype p
Page 49 and 50: Review of Literature 2.7.2 Biologic
Page 51 and 52: Review of Literature Table 1: Steps
Page 53 and 54: Review of Literature future analysi
Page 55 and 56: Review of Literature Inefficient ce
Page 57 and 58: Review of Literature XRCC1 (X-ray r
Page 59 and 60: Review of Literature 2.9.2 Gene inv
Page 61 and 62: Review of Literature MPO gene polym
Page 63 and 64: Review of Literature important role
Page 65 and 66: Materials and Methods Source of che
Page 67 and 68: Materials and Methods Method: EBV-t
Page 69 and 70: Materials and Methods Immunophenoty
Page 71 and 72: Materials and Methods with 500 μl
Page 73 and 74: Materials and Methods cDNA it can b
Page 75 and 76: Materials and Methods Cobalt-60 iso
Page 77 and 78: Materials and Methods specific bind
Page 79 and 80: Materials and Methods h half of the
Page 81 and 82: Materials and Methods phenol and th
Page 83 and 84: Materials and Methods 7. Filter ste
Page 85 and 86: Materials and Methods viz. EXO-SAP
Page 90 and 91: Materials and Methods SMAD6 AREG HM
Page 92 and 93: Materials and Methods 3.9 Effect of
Page 94 and 95: Materials and Methods fresh eppendo
Page 96 and 97: Materials and Methods Power SYBR Gr
Page 98 and 99: Results Objective 1 To generate EBV
Page 100 and 101: Results Fig. 8: Frequency of second
Page 102 and 103: Results Table 6: Demographics of he
Page 104 and 105: Results Fig. 10: Cell population do
Page 106 and 107: Results Fig. 12: Cell surface marke
Page 108 and 109: Results 4.1.5 Expression of ATM gen
Page 110 and 111: Results Objective 2 To compare the
Page 112 and 113: Results Fig. 17: Standardization of
Page 114 and 115: Results Fig. 19: Standardisation of
Page 116 and 117: Results The cells were incubated fu
Page 118 and 119: Results 4.2.3.1 Percent G2 delay af
Page 120 and 121: Results 4.2.3.2 Effect of BPDE expo
Page 122 and 123: Results Fig. 29: Comparison of perc
Page 124 and 125: Results Fig. 31: Percent cell death
Page 126 and 127: Results normalization with baseline
Page 128 and 129: Results 4.2.5.2 Real time PCR valid
Page 130 and 131: Results homozygous wild-type, heter
Page 132 and 133: Results Fig. 36b: Electrophoresis o
Page 134 and 135: Results Fig. 37a: Representative el
Page 136 and 137: Results Table 13: Consolidated geno
Page 138 and 139:
Results LCL Genes NAT2(1) NAT2(2) N
Page 140 and 141:
Results Fig. 38: Distribution of Ge
Page 142 and 143:
Results Fig. 39: Various combinatio
Page 144 and 145:
Results Table 14: Genotype-phenotyp
Page 146 and 147:
Discussion Introduction Squamous ce
Page 148 and 149:
Discussion stimulated lymphocytes w
Page 150 and 151:
Discussion H2AX is currently the mo
Page 152 and 153:
Discussion or G2/M phase arrest. As
Page 154 and 155:
Discussion differential expression
Page 156 and 157:
Discussion DNA repair genes and MPN
Page 158 and 159:
Chapter 6 Summary and Conclusions
Page 160 and 161:
Summary and Conclusions Statistical
Page 162 and 163:
Bibliography 1. Dikshit, R.; Gupta,
Page 164 and 165:
Bibliography 43. Lei, D.; Sturgis,
Page 166 and 167:
Bibliography 76. Fry, R. C.; Svenss
Page 168 and 169:
Bibliography 115. Kote-Jarai, Z.; M
Page 170 and 171:
Bibliography 149. Hashibe, M.; Bren
Page 172 and 173:
Bibliography 183. Bergamaschi, D.;
Page 174 and 175:
Bibliography 216. Bondy, M. L.; Wan
Page 176 and 177:
Indian J Med Res 135, June 2012, pp
Page 178 and 179:
822 INDIAN J MED RES, JUNE 2012 mar
Page 180 and 181:
824 INDIAN J MED RES, JUNE 2012 (h)
Page 182 and 183:
826 INDIAN J MED RES, JUNE 2012 Tab
Page 184 and 185:
828 INDIAN J MED RES, JUNE 2012 lik
Page 186 and 187:
CASE REPORT Eben L. Rosenthal, MD,
Page 188 and 189:
FIGURE 2. Chromosomal breakage anal
Page 190 and 191:
FA along with ataxia telangiectasia
show all

LIFE09200604007 Tabish - Homi Bhabha National Institute

Create successful ePaper yourself

Delete template?

Save as template?